EHP Funds Inc. Makes New Investment in Gilead Sciences, Inc. $GILD

EHP Funds Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 5,929 shares of the biopharmaceutical company’s stock, valued at approximately $658,000. Gilead Sciences comprises 0.6% of EHP Funds Inc.’s investment portfolio, making the stock its 28th biggest position.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Corundum Trust Company INC bought a new stake in Gilead Sciences in the third quarter worth $26,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter worth $30,000. MTM Investment Management LLC raised its holdings in Gilead Sciences by 176.0% during the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 176 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Gilead Sciences in the second quarter worth about $33,000. Finally, Millstone Evans Group LLC lifted its position in shares of Gilead Sciences by 58.7% in the third quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 118 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the transaction, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This represents a 16.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 309,280 shares of company stock worth $43,935,470. 0.27% of the stock is owned by insiders.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Mizuho boosted their target price on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday, February 18th. Citigroup reaffirmed a “buy” rating on shares of Gilead Sciences in a research report on Friday, March 6th. Oppenheimer increased their price target on Gilead Sciences from $128.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, February 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $170.00 price objective on shares of Gilead Sciences in a research note on Monday, February 23rd. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $157.62.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst optimism — Jefferies and other firms have initiated or reiterated positive coverage, highlighting Gilead’s strong HIV franchise, expanding oncology/cell therapy pipeline and long IP runway (through ~2036), which supports both income and growth narratives. How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story
• Positive Sentiment: Zacks raised near-term EPS estimates (Q1/Q2 and FY2027 upgrades reported), nudging earnings expectations higher — a constructive signal for investors focused on fundamentals. The Zacks Analyst Blog: Oracle, T‑Mobile, Gilead and C&F Financial
• Positive Sentiment: Unusually large call-option activity (130k+ calls) signals bullish positioning by traders, which can amplify upside if catalysts continue. (Market data)
• Positive Sentiment: Index and institutional flows — rising institutional focus amid Nasdaq‑100 dynamics can support demand for GILD shares from passive and quant funds. Gilead (NASDAQ:GILD) Institutional Focus Rises In Nasdaq 100 Index
• Neutral Sentiment: Acquisition rationale — coverage and analyst pieces discuss whether the ~$7.8B Arcellx buy strengthens Gilead’s cell‑therapy franchise amid declining cell therapy sales; the strategic case is positive but clinical/commercial risks remain. Will GILD’s Move to Acquire ACLX Boost Its Cell Therapy Franchise?
• Neutral Sentiment: Market context — broader investor flows into growth/tech vs. traditional defensives are affecting healthcare sector moves; this macro backdrop is neither uniquely positive nor negative for Gilead. Why Investors Aren’t Fleeing to Safe‑Haven Stocks
• Negative Sentiment: Deal/legal risk — a law firm (Kahn Swick & Foti) is investigating Arcellx’s proposed sale to Gilead, citing concerns over price/process; shareholder litigation or regulatory scrutiny could delay or alter the transaction terms and is a near‑term overhang. Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $144.99 on Friday. The business has a 50 day moving average price of $140.62 and a 200 day moving average price of $126.78. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a market cap of $179.99 billion, a price-to-earnings ratio of 21.42, a PEG ratio of 1.90 and a beta of 0.37. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the previous year, the business posted $1.90 EPS. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s dividend payout ratio is 46.68%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.